Further analysis identified a significant association between SLC16A1-AS1 expression levels and pathological staging in eight specific cancer types: Bladder Urothelial Carcinoma (BLCA), Breast Invasive Carcinoma (BRCA), Head and Neck Squamous Cell Carcinoma (HNSC), Kidney Chromophobe (KICH), Kidney Renal Clear Cell Carcinoma (KIRC), Kidney Renal Papillary Cell Carcinoma (KIRP), Liver Hepatocellular Carcinoma (LIHC), and Thyroid Carcinoma (THCA) (Fig. 1B). The gene discussed is SLC16A1; the disease is bladder transitional cell carcinoma.